Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded at Zacks Research

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Finally, Wells Fargo & Company upped their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Milestone Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Milestone Pharmaceuticals Stock Up 3.6%

MIST stock opened at $2.01 on Monday. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. The company’s 50 day simple moving average is $2.24 and its 200-day simple moving average is $1.96. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $3.06. The firm has a market capitalization of $171.19 million, a PE ratio of -2.45 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05. Equities analysts expect that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Insider Activity at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00. Following the transaction, the chief executive officer owned 303,721 shares in the company, valued at approximately $683,372.25. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Propel Bio Management LLC lifted its position in shares of Milestone Pharmaceuticals by 186.1% in the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after buying an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in Milestone Pharmaceuticals in the 3rd quarter worth approximately $6,444,000. Simplify Asset Management Inc. lifted its holdings in Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares during the last quarter. Pathstone Holdings LLC bought a new stake in Milestone Pharmaceuticals during the third quarter worth approximately $2,000,000. Finally, Boxer Capital Management LLC acquired a new position in Milestone Pharmaceuticals during the third quarter valued at approximately $1,333,000. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.